<?xml version="1.0"?>
<data><body>

<para><drugname>DrugB</drugname> increases the risk of bleeding. <drugname>DrugB</drugname> is contraindicated in patients with the following clinical situations in which bleeding could be associated with a high risk of death or significant morbidity:
</para>

<list>
<item>Active internal bleeding</item>
<item>Recent (within 3 months) hemorrhagic stroke</item>
<item>Recent (within 2 months) intracranial or intraspinal surgery, or severe head trauma</item>
<item>Trauma with an increased risk of life-threatening bleeding</item>
<item>Presence of an epidural catheter</item>
<item>Intracranial neoplasm or mass lesion or evidence of cerebral herniation</item>
<item><drugname>DrugB</drugname> is contraindicated in patients with known hypersensitivity to drotxxxxgin alxa (activated) or any component of this product.</item>
</list>

</body></data>

